16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy

      1 , 2 , 1 , 2 , 3 , 1 , 2 , 1 , 2 , 4 , 5
      ACS Nano
      American Chemical Society (ACS)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Photodynamic therapy (PDT) is an effective, noninvasive therapeutic modality against local tumors that are accessible to the source of light. However, it remains challenging to apply PDT for the treatment of disseminated, metastatic cancer. On the other hand, cancer immunotherapy offers a promising approach for generating systemic antitumor immune responses against disseminated cancer. Here we report a multifunctional nanomaterial system for the combination of PDT and personalized cancer immunotherapy and demonstrate their potency against local as well as disseminated tumors. Specifically, we have synthesized uniform and biodegradable mesoporous silica nanoparticles (bMSN) with an average size of ~80 nm and large pore size of 5–10 nm for theranostic positron emission tomography (PET)-guided PDT and neoantigen-based cancer vaccination. Multiple neoantigen peptides, CpG oligodeoxynucleotide adjuvant, and photosensitizer chlorin e6 were coloaded into a bMSN nanoplatform, and PET imaging revealed effective accumulation of bMSN in tumors (up to 9.0% ID/g) after intravenous administration. Subsequent PDT with laser irradiation recruited dendritic cells to PDT-treated tumor sites and elicited neoantigen-specific, tumor-infiltrating cytotoxic T-cell lymphocytes. Using multiple murine models of bilateral tumors, we demonstrate strong antitumor efficacy of PDT-immunotherapy against locally treated tumors as well as distant, untreated tumors. Our findings suggest that the bMSN is a promising platform for combining imaging and PDT-enhanced personalized immunotherapy for the treatment of advanced cancer.

          Related collections

          Author and article information

          Journal
          ACS Nano
          ACS Nano
          American Chemical Society (ACS)
          1936-0851
          1936-086X
          September 25 2019
          October 22 2019
          September 26 2019
          October 22 2019
          : 13
          : 10
          : 12148-12161
          Affiliations
          [1 ]Department of Pharmaceutical Science, University of Michigan, Ann Arbor, Michigan 48109, United States
          [2 ]Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48109, United States
          [3 ]Department of Radiology, Center for Molecular Imaging, University of Michigan, Ann Arbor, Michigan 48109, United States
          [4 ]Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan 48109, United States
          [5 ]Graduate Program in Immunology, University of Michigan, Ann Arbor, Michigan 48109, United States
          Article
          10.1021/acsnano.9b06691
          6832743
          31556987
          f6c128a2-432a-4d5a-ab7f-5b04251d5b9d
          © 2019
          History

          Comments

          Comment on this article